Search

Your search keyword '"Andrews, Christopher N."' showing total 34 results
Start Over Author "Andrews, Christopher N." Journal gastroenterology (00165085)
34 results on '"Andrews, Christopher N."'

4. Sa2023 TARGETED AND REPRODUCIBLE SAMPLING OF THE SMALL INTESTINAL MICROBIOME WITH THE SMALL INTESTINE MICROBIOME ASPIRATE CAPSULE TECHNOLOGY (SIMBA): CLINICAL VALIDATION AGAINST ENDOSCOPY ASPIRATES AND FECAL SAMPLES IN HEALTHY AND GI DISORDER.

Author

Bundalovic-Torma, Cedoljub, Wang, Gang, Menon, Sharanya, Bruehlmann, Sabina, Wilsack, Lynn, Rehak, Renata, Bagheri, Sahar, Banoei, Mohammad, Lou, Lawrence, Nasser, Yasmin, Woo, Matthew, Lewis, Ian, McCoy, Kathy, and Andrews, Christopher N.

Published
2024
Full Text
View/download PDF

13. Alterations in Expression of p11 and SERT in Mucosal Biopsy Specimens of Patients With Irritable Bowel Syndrome.

Author

Camilleri, Michael, Andrews, Christopher N., Bharucha, Adil E., Carlson, Paula J., Ferber, Irene, Stephens, Debra, Smyrk, Thomas C., Urrutia, Raul, Aerssens, Jeroen, Thielemans, Leen, Göhlmann, Hinrich, van den Wyngaert, Ilse, and Coulie, Bernard

Subjects
PATHOLOGICAL physiology, IRRITABLE colon, MESSENGER RNA, ANTIDEPRESSANTS
Abstract

Background & Aims: The pathophysiology of irritable bowel syndrome (IBS) remains enigmatic; abnormalities in serotonin metabolism have been implicated. Two proteins that influence the function of serotonin and serotonergic receptors are serotonin transporter protein (SERT or soluble carrier protein, SLC6A4) and p11 (S-100A10, or calpactin I light chain). Both proteins are reported to be associated with depression-like states, a frequent comorbid condition in IBS. We explored the hypothesis that expression of these 2 proteins in colonic and rectal mucosa is abnormal in patients with IBS as compared with healthy controls. Methods: Messenger RNA (mRNA) expression of SLC6A4 and p11 was measured in sigmoid and rectal mucosal biopsy specimens. Genotype of the promoter for SLC6A4 was also assessed in all participants. Validation studies explored reproducibility of 2 biopsy specimens taken from the same region and biopsy specimens taken an average of ∼3 months apart. Results: We found normal colonic mucosal expression of SLC6A4 in diarrhea (IBS-D)- or constipation-predominant IBS (IBS-C). On the other hand, p11 expression was increased in IBS. No significant effect on p11 mRNA expression in sigmoid colon or rectum was noted from antidepressant treatment in any of the analyzed subgroups. Conclusions: Colonic mucosal expression of SLC6A4 in IBS is normal. Given that overexpression of p11 can increase serotonergic receptor functions (eg, 5-HT1B receptors), these data support the need for further study of the interaction between p11 expression in health and disease and its role in the therapeutic response to serotonergic agents, including antidepressants. [Copyright &y& Elsevier]

Published
2007
Full Text
View/download PDF

18. Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide Analysis.

Author

Ma, Christopher, Congly, Stephen E., Novak, Kerri L., Belletrutti, Paul J., Raman, Maitreyi, Woo, Matthew, Andrews, Christopher N., and Nasser, Yasmin

Abstract

Functional bowel disorders (FBDs) are the most common gastrointestinal problems managed by physicians. We aimed to assess the burden of chronic symptomatic FBDs on ambulatory care delivery in the United States and evaluate patterns of treatment. Data from the National Ambulatory Medical Care Survey were used to estimate annual rates and associated costs of ambulatory visits for symptomatic irritable bowel syndrome, chronic functional abdominal pain, constipation, or diarrhea. The weighted proportion of visits associated with pharmacologic and nonpharmacologic (stress/mental health, exercise, diet counseling) interventions were calculated, and predictors of treatment strategy were evaluated in multivariable multinomial logistic regression. From 2007–2015, approximately 36.9 million (95% CI, 31.4–42.4) weighted visits in patients of non-federally employed physicians for chronic symptomatic FBDs were sampled. There was an annual weighted average of 2.7 million (95% CI, 2.3–3.2) visits for symptomatic irritable bowel syndrome/chronic abdominal pain, 1.0 million (95% CI, 0.8–1.2) visits for chronic constipation, and 0.7 million (95% CI, 0.5–0.8) visits for chronic diarrhea. Pharmacologic therapies were prescribed in 49.7% (95% CI, 44.7–54.8) of visits compared to nonpharmacologic interventions in 19.8% (95% CI, 16.0–24.2) of visits (P <.001). Combination treatment strategies were more likely to be implemented by primary care physicians and in patients with depression or obesity. The direct annual cost of ambulatory clinic visits alone for chronic symptomatic FBDs is approximately US$358 million (95% CI, 233–482 million). The management of chronic symptomatic FBDs is associated with considerable health care resource use and cost. There may be an opportunity to improve comprehensive FBD management because fewer than 1 in 5 ambulatory visits include nonpharmacologic treatment strategies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results